Verona Pharma

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD and cystic fibrosis. The Company is listed on the NASDAQ Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative theraputics.

Latest press releases

22 February 2018

Verona Pharma to Announce Operational Update and Financial Results for Full Year ended December 31, 2017
LONDON, Feb. 22, 2018 (GLOBE NEWSW…

13 February 2018

Verona Pharma Provides Clinical Development Update
LONDON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Ver…

Financing Deal of the Year

Verona Pharma receives Financing Deal of the Year at the 2017 Scrip Awards for its successful fundraising to support the continued growth of its clinical development programmes

29 November 2017

 

Current share price

132.50p

10.00 (8.16%)

LON: VRP
 

15.25USD

1.39 (10.02%)

NASDAQ: VRNA
 

Contact us

Verona Pharma plc
3 More London Riverside
London SE1 2RE
United Kingdom

E: info@veronapharma.com
T: +44 (0)203 283 4200

 

 

Registered address
One Central Square
Cardiff CF10 1FS
United Kingdom

US Investor relations contact
ICR, Inc.
E: ICR_Verona@icrinc.com
T: +1 646-277-1282

UK Investor relations contact
FTI Consulting
E: veronapharma@fticonsulting.com
T: +44 (0)20 3727 1000

Nominated adviser and broker
Stifel Nicolaus Europe Limited
150 Cheapside
London EC2V 6ET
United Kingdom

T: +44 (0)207 710 7600

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us